Tianjin Xinglian Peptide Biotechnology

Conjustar operates in the biotechnology sector, focusing on the development of miniaturized conjugated drugs to treat solid tumors. The company serves pharmaceutical companies, research institutions, and healthcare providers. Conjustar leverages its globally excellent technology platform to create novel drugs, including PDC (Peptide-Drug Conjugates) and NDC (Nanoparticle-Drug Conjugates). The business model revolves around research and development, clinical trials, and partnerships with other biotech firms and healthcare organizations. Revenue is generated through licensing agreements, research grants, and collaborative projects.

Keywords: Biotech, Conjugated Drugs, Solid Tumors, PDC, NDC, Drug Development, Clinical Trials, Healthcare, Pharmaceutical, Research.